Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • For Subscribers
    • For Advertisers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • For Subscribers
    • For Advertisers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Antimineralocorticoid 11β-Substituted Spirolactones Exhibit Androgen Receptor Agonistic Activity: A Structure Function Study

Philippe Nirdé, Béatrice Térouanne, Nadine Gallais, Charles Sultan and Gilles Auzou
Molecular Pharmacology May 2001, 59 (5) 1307-1313; DOI: https://doi.org/10.1124/mol.59.5.1307
Philippe Nirdé
1Institut National de la Santé et de la Recherche Médicale U439, Pathologie Moléculaire des Récepteurs Nucléaires (P.N., B.T., N.D., C.S., G.A); 2Laboratoire d'Hormonologie du Développement et de la Reproduction, Hôpital Lapeyronie (C.S); and 3Unité d'Endocrinologie Pédiatrique, Pédiatrie 1, CHU Hôpital A. de Villeneuve (C.S.), Montpellier, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Béatrice Térouanne
1Institut National de la Santé et de la Recherche Médicale U439, Pathologie Moléculaire des Récepteurs Nucléaires (P.N., B.T., N.D., C.S., G.A); 2Laboratoire d'Hormonologie du Développement et de la Reproduction, Hôpital Lapeyronie (C.S); and 3Unité d'Endocrinologie Pédiatrique, Pédiatrie 1, CHU Hôpital A. de Villeneuve (C.S.), Montpellier, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nadine Gallais
1Institut National de la Santé et de la Recherche Médicale U439, Pathologie Moléculaire des Récepteurs Nucléaires (P.N., B.T., N.D., C.S., G.A); 2Laboratoire d'Hormonologie du Développement et de la Reproduction, Hôpital Lapeyronie (C.S); and 3Unité d'Endocrinologie Pédiatrique, Pédiatrie 1, CHU Hôpital A. de Villeneuve (C.S.), Montpellier, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charles Sultan
1Institut National de la Santé et de la Recherche Médicale U439, Pathologie Moléculaire des Récepteurs Nucléaires (P.N., B.T., N.D., C.S., G.A); 2Laboratoire d'Hormonologie du Développement et de la Reproduction, Hôpital Lapeyronie (C.S); and 3Unité d'Endocrinologie Pédiatrique, Pédiatrie 1, CHU Hôpital A. de Villeneuve (C.S.), Montpellier, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gilles Auzou
1Institut National de la Santé et de la Recherche Médicale U439, Pathologie Moléculaire des Récepteurs Nucléaires (P.N., B.T., N.D., C.S., G.A); 2Laboratoire d'Hormonologie du Développement et de la Reproduction, Hôpital Lapeyronie (C.S); and 3Unité d'Endocrinologie Pédiatrique, Pédiatrie 1, CHU Hôpital A. de Villeneuve (C.S.), Montpellier, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

In humans, spironolactone and mespirenone are well known antimineralocorticoids without C-11β substituents. These compounds display antagonist properties by acting through the human androgen receptor (hAR). In contrast, we demonstrate here that synthetic mineralocorticoid antagonists bearing hydrophobic C-11β substituents and C-17γ-lactone are potent hAR agonists in vitro. The three-dimensional construction of both the ligand binding domain (LBD) of the hAR and the human mineralocorticoid receptor (hMR), based on the crystal structure of the LBD of the human progesterone receptor, revealed not only that the interactions with the steroidal A- and D-rings seemed to be crucial for stabilization of active hMR or hAR conformation, but that other steroidal substitutions could influence the agonist versus antagonist activity of ligands. The docking of synthetic compounds bearing C-11β hydrophobic substituents within the ligand binding pocket of hAR demonstrated that precise positions of the steroid, such as C-11 and C-17, are in close contact with some residues on the receptor, C-11 with Gly 708 and C-17 with Asn705 and Thr877. These contacts are crucial for the stabilization of the active receptor conformation. Mutation of Asn705 by alanine altered the 11β-substituted spirolactone-mediated trans-activation function of hAR, suggesting an anchoring of the C-17-lactone carbonyl group (C-22) with this residue. The stabilizing effect of the H12 helix in its active conformation is also induced by hydrophobic contacts between the Gly708 and C-11β substituents, as recently observed with the A773G-hMR mutant in the presence of similar drugs. The study of the role of these substituents suggests efficient new directions for the drug design of selective androgen agonists.

Footnotes

    • Received October 23, 2000.
    • Accepted February 2, 2001.
  • Send reprint requests to: Dr. Gilles Auzou, INSERM U439, Pathologie Moléculaire des Récepteurs Nucléaires, 70, rue de Navacelles, 34090 Montpellier, France. E-mail:auzou{at}montp.inserm.fr

  • This work was supported by the Institut National de la Santé et de la Recherche Médicale (INSERM), the Association pour la Recherche sur le Cancer (ARC no. 5205: 1999), and the Fondation pour la Recherche Médicale (FRM).

  • This work was presented as a poster at the 14th International Symposium of the Journal of Steroid Biochemistry & Molecular Biology; Quebec, Canada; 2000 June.

  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

Log in using your username and password

Forgot your user name or password?

Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$35.00

Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.

PreviousNext
Back to top

In this issue

Molecular Pharmacology: 59 (5)
Molecular Pharmacology
Vol. 59, Issue 5
1 May 2001
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Antimineralocorticoid 11β-Substituted Spirolactones Exhibit Androgen Receptor Agonistic Activity: A Structure Function Study
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
Citation Tools
Research ArticleArticle

Antimineralocorticoid 11β-Substituted Spirolactones Exhibit Androgen Receptor Agonistic Activity: A Structure Function Study

Philippe Nirdé, Béatrice Térouanne, Nadine Gallais, Charles Sultan and Gilles Auzou
Molecular Pharmacology May 1, 2001, 59 (5) 1307-1313; DOI: https://doi.org/10.1124/mol.59.5.1307

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleArticle

Antimineralocorticoid 11β-Substituted Spirolactones Exhibit Androgen Receptor Agonistic Activity: A Structure Function Study

Philippe Nirdé, Béatrice Térouanne, Nadine Gallais, Charles Sultan and Gilles Auzou
Molecular Pharmacology May 1, 2001, 59 (5) 1307-1313; DOI: https://doi.org/10.1124/mol.59.5.1307
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Operational Models for Receptors with Multiple Agonist Sites
  • BODIPY-cyclopamine Binding to Nluc-SMO
  • Characterization and optimization of the novel TRPM2 antagonist tatM2NX
Show more Article

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2019 by the American Society for Pharmacology and Experimental Therapeutics